Research Article

18F-FDG-PET/CT Imaging in Advanced Glottic Cancer: A Tool for Clinical Decision in Comparison with Conventional Imaging

G. Paone,¹ F. Martucci,² V. Espeli,³ L. Ceriani,¹ G. Treglia,¹ T. Ruberto,¹ A. Richetti,² R. Piantanida,⁴ and L. Giovanella ¹

¹Department of Nuclear Medicine and PET/CT Centre, Imaging Institute of Southern Switzerland, Bellinzona, Switzerland
²Department of Radiotherapy, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
³Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
⁴Department of Otolaryngology-Head and Neck Surgery, Ospedale Regionale di Lugano, Lugano, Switzerland

Correspondence should be addressed to G. Paone; gaetano.paone@eoc.ch

Received 5 February 2019; Revised 8 April 2019; Accepted 7 July 2019; Published 11 September 2019

Guest Editor: Antonella Zannetti

Copyright © 2019 G. Paone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study assessed the role of ¹⁸F-FDG PET-CT (PET/CT) to detect the cartilage and paraglottic infiltration in advanced glottic cancer comparing the results with those of conventional imaging (CI) (contrast-enhanced computed tomography and/or magnetic resonance). In addition, we assessed the prognostic value of quantitative parameters, measured on baseline PET/CT, in terms of event-free survival (EFS) and overall survival (OS). We retrospectively analyzed 27 patients with glottic squamous cell carcinoma stage III and IVA, treated in our institute between 2010 and 2016, comparing PET/CT, performed for staging and radiotherapy planning, and CI findings. Cohen’s K was used to compare concordance between PET/CT and CI. Imaging findings were correlated with endoscopic evaluation and histological reports (gold standard (GS)). All lesions shown by CI were also detected by PET/CT imaging, and in 5 cases, a better definition of local infiltration was achieved with PET/CT than CI (5 CT). Sensitivity, specificity, and accuracy of PET/CT and CT were 95%, 86%, and 93% and 70%, 86%, and 74% for, respectively. MRI showed sensitivity and specificity of 100%. One false-negative (FN) case and 1 false-positive (FP) case were observed with PET/CT with no difference compared to MRI (10 cases). Six FN cases and 1 FP case were observed with CT. Cohen’s K was 0.60 (PET vs. CI) and 0.80 (PET vs. GS). Patients were followed-up for at least 24 months to calculate EFS and OS. 13 local recurrences and 7 deaths were recorded. Among quantitative PET parameters, baseline MTV was the most powerful predictor of outcome. Our data suggest a reliable sensitivity and accuracy of PET/CT in the evaluation of local extension, proving a useful method for initial local staging in addition to the well-established role in lymph-node and distant sites assessment. Furthermore, pretreatment MTV provides better prognostic information than other PET/CT parameters.

1. Introduction

Glottic cancer (GC) is a common malignant tumor in the head and neck region. Histologically, more than 95% of these tumors are represented by squamous cell carcinoma (SCC) [1–3]. Staging of primary glottic SCC (GSCC) is based on clinical examination using indirect and direct endoscopy to evaluate larynx involvement or adjacent regions of the pharynx, as well as vocal cord mobility. Additional imaging procedures are required in advanced cases to accurately evaluate the invasion of submucosal tissue and extension into deep planes [4, 7]. T3 lesions have extension into the paraglottic and/or preepiglottic space, irrespective of vocal cord mobility and tumor invasion limited to the inner cortex of the thyroid cartilage. T4a lesions are characterized instead by extralaryngeal tumor spread and invasion through the thyroid cartilage.

Different therapeutic approaches can be considered, depending on the stage: organ preservation treatments as radiation therapy, chemoradiation protocols, or function-preserving partial surgery, namely, for T3 lesions. More aggressive treatments up to total laryngectomy are indicated in patients with T4a disease, particularly when the tumor extends through the cartilage into the soft tissues [5–9].
Conventional imaging (CI) (contrast-enhanced CT (CECT) and MRI) is mandatory to complete the staging process, assessing tumor extent and to detect and define nodal disease. Larynx cancer is frequently evaluated with CECT which is less affected by breathing and swallowing artifacts, while MRI should be preferred for nasopharyngeal, sinonasal, and parotid tumors for a better contrast resolution and detection of perineural spread [10, 11]. $^{18}$F-FDG PET/CT (PET/CT) instead shows clear advantage, compared to CI, for assessment of subclinical nodal disease, distant metastases, and evaluation of the treatment results [12, 13].

Cartilage invasion plays a crucial role in local staging of GSCC, an important landmark to qualify a T4a stage. The characteristic pattern on CT image is represented by sclerosis and invasion in thyroid, cricoid, and arytenoid cartilage, in combination with extralaryngeal infiltration. In such cases, the MRI findings (i.e., high signal intensity in T2 sequences and a low/intermediate signal in T1) are indistinguishable from those found in reactive inflammation, edema and fibrosis. In addition, MRI is costly and time consuming compared to CT and, as a consequence, the latter is the preferred technique to evaluate the primary site and the possible nodal involvement [10]. On the other hand, PET/CT proved to be more sensitive and accurate in detecting distant metastases and any second tumor and as a prognostic index, especially by using semiquantitative parameters (i.e., standard uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG)) [14–20]. In addition, promising preliminary result was also reported in locoregional staging, on management of radiotherapy plan, demonstrating an improvement on dosimetry by lowering dose to certain organs at risk, and in comparison with panendoscopy to detect unknown secondary primary tumors [21–24].

In our retrospective study, we assessed the diagnostic accuracy of PET/CT for advanced glottic cancer, considering laryngeal cartilage infiltration rates (sensitivity, specificity, accuracy, negative predictive value (NPV), and positive predictive value (PPV)) and paraglottic infiltration. We eventually have compared PET/CT with CECT and MRI. Histological specimen analyses were used as standard of reference. Finally, we assessed the prognostic value of quantitative parameters, measured on baseline PET/CT, in terms of event-free survival (EFS) and overall survival (OS).

2. Materials and Methods

Records of 31 patients with histologically confirmed advanced GSCC (stage T3–T4a) treated between January 2010 and December 2016 in our institute were retrieved and reviewed. 4 patients were excluded for lack of data on follow-up. 27 patients (mean age 67.1 years; range 55–80, 3 females and 24 males) undergoing complete endoscopic workout and surgical treatment (total laryngectomy with or without thyroidectomy) were eventually included. PET/CT and CECT were performed, as staging procedures, within two weeks after panendoscopy and before any treatment [25]. In addition to PET/CT and CECT, a MRI examination was performed in 10 patients.

A nuclear medicine physician and a radiologist specialized in head and neck imaging reviewed PET/CT and CI, respectively, in a double-blind method. Initially, PET/CT data were visually analyzed to identify focal FDG uptake corresponding to the primary lesion that resulted significantly higher than background activity of surrounding tissues (at least 3 times higher) and to evaluate whether FDG-avid area overlapped the laryngeal cartilage framework, using the coregistered low-dose CT images. Fused images were then elaborated on the three orthogonal planes to visualized disease’s extension on the surrounding region (supra- and subglottis space) while axial plane was dedicated to assess possible infiltration of laryngeal cartilage and involvement of extralaryngeal tissue. Semiquantitative analysis was performed using a semiautomated circular 3D VOI that allowed to calculate SUVmax, peak, MTV in cm³, and TLG (contouring program on Syngo TrueD workstation, Siemens). CECT images were analyzed to define the cartilage involvement based on a combination of invasion, erosion and transmural extralaryngeal spread. Finally, on MRI, Becker’s criteria were used to identify the suspected cartilage invasion comparing T2-weighted and contrast-enhanced T1-weighted signal [26–28].

Patients were followed-up for at least 24 months to calculate EFS and OS. Follow-up consisted in head and neck specific examination and exploration of the inner structures using endoscopic procedure (mirror and a flexible endoscope) every 3 months during the first two years. Imaging procedures (PET/CT and eventually contrast-enhanced CT) were performed every year for the first 2 years; subsequent imaging studies were considered in case of clinical suspicion of disease recurrence. EFS was defined as the time from diagnosis to disease progression (relapse or death) and OS as the time from diagnosis to death.

Statistical analysis was carried out using SPSS for Windows. The agreement test (Cohen’s Kappa) was used to compare imaging modality with the histological findings (GS). When appropriate, the Fisher test was used and $p$ value < 0.05 was considered statistically significant. PET/CT-derived parameters (SUVmax, MTV, and TLG) were analyzed using receiver-operating characteristic (ROC) analysis to identify the optimal cutoff point. The area under the ROC curve (AUC) and the diagnostic accuracy for recurrence and death were used to select the best method. EFS and OS, chosen as endpoints to evaluate prognosis, were estimated using the Kaplan–Meier method. Logistic regression and Cox proportional-hazards regression were performed to test the significance of SUVmax, MTV, and TLG.

3. Results

On the basis of histological findings, our patients were included into two groups: T4a showing infiltration of the cartilaginous structures and extralaryngeal spread (20/27 (74%)) and T3 without cartilage infiltration and tissue invasion (7/27 patients (26%)) (Figures 1 and 2).

As summarized in Table 1, PET/CT and CECT correctly detected cartilage infiltration and extralaryngeal invasion, respectively, in 19 and 14 of 20 patients of the T4a group.
Both methods correctly excluded cartilage infiltration and extralaryngeal invasion in 6/7 patients with T3 stage, with one false positive (FP) in the same patient (Figure 2). We found one false negative (FN) in PET/CT and six in CECT. In summary, the sensitivity and specificity for PET/CT were, respectively, 95% and 86% (95% CI: 75% to 99%; 48% to 97%) while for CECT were 70% and 86% (95% CI: 46% to 85%; 49% to 97%). PET/CT had accuracy, PPV, and NPV, respectively, of 93%, 95%, and 86% vs. 74%, 93%, and 50% of CECT. Finally, MRI was also performed in 7 of 20 T4a patients showing sensitivity and specificity of 100% (95% CI 64% to 100%; 44% to 100%). Area under the receiver-operating characteristic curve for cartilage infiltration detected by PET/CT (0.90) was significantly larger than that of CECT (0.77) (p = 0.001) (Figures 3 and 4).

Coefficient of agreement between imaging modality and histological findings was excellent for PET/CT (k = 0.805) and MRI (k = 1.00) while it resulted moderate for CECT (k = 0.442). Coefficient of agreement calculated between different imaging methods was excellent for PET/CT vs. MRI (k = 1.00) and good for PET/CT vs. CECT and MRI vs. CECT (k = 0.604). No significant differences, in terms of local staging, were found between the two groups using the semi-quantitative analysis.

After a median follow-up of 37 ± 10.6 months, 13 local recurrence (within 15 ± 8.5 months) and 7 deaths (within 26 ± 14 months) were recorded.

The optimal SUVmax, MTV, and TLG cutoff values to discriminate subgroups with different event-free (EFS) and overall survival (OS) have been defined by ROC curve analysis (Tables 2 and 3). As summarized in Table 4, we calculated sensitivity (Se.), specificity (Sp.), positive predictive value (PPV), negative predictive value (NPV), and accuracy (Acc.) of these cutoff values to predict recurrence and death.

High values of MTV, SUVmax, and TLG showed a statistically significant association with worse EFS, but only MTV retained statistical significance for both OS and EFS, yielding the best prediction of recurrence and death (Table 5, Figures 5 and 6). Cox proportional-hazards regression showed that age, sex, staging, and TNM classification were not related to the patients’ outcome. There was a significant difference for predicting EFS (p < 0.001; HR 7.3518, 95% CI 2.4505 to 22.0570) and OS (p < 0.009; HR 9.4105, 95% CI 2.3180 to 38.2045) for patients with high MTV (cutoff EFS MTV > 18.6 cm³ and OS MTV > 22.4 cm³) vs. low MTV. The estimated 3-year EFS (median 44 months, 95% CI 39.836 to 49.331) was 83% for patients with low MTV vs. 26% for those with high MTV. 3-year OS (median 47 months, 95% CI 45.141 to 48.859) was 92% vs. 50%, respectively (Figures 7 and 8). Global overall survival was 74% (20/27 pts). Long-term outcome was significantly better for patients with lower MTV values compared with those with high MTV values. Among quantitative PET/CT parameters, baseline MTV was the most powerful predictor of outcome.

4. Discussion

According to the latest treatment guidelines [4], advanced glottic SCC with cartilage invasion and extralaryngeal tissue infiltration favors total laryngectomy followed by radiotherapy and chemotherapy rather than approaches based on organ preservation protocols [29]. Imaging techniques are...
mandatory in addition to clinical and endoscopic examinations for an appropriate staging of the disease [30]. Several studies highlighted the impact of conventional imaging methods for detection of cartilage invasion in advanced GSCC showing a high sensitivity (94% vs. 67%) and a low specificity (74% vs. 87%) for MRI compared to CECT [27, 31, 32]. Recently, Becker et al. proposed new diagnostic MRI criteria to increase specificity up to 84% without affecting sensitivity [28]. Metabolic imaging by 18F-FDG-PET/CT may improve the accuracy of head and neck cancer (HNC) staging, distinguish residual or recurrent disease from posttherapeutic changes, differentiate early responders patients from nonresponders, and provide prognostic data [33–36]. However, so far, there are few published data defining the role of PET/CT on the local staging of advanced glottic cancer and, therefore, selecting the treatment options [16, 37, 38]. Our study provides preliminary data supporting the valuable accuracy of PET/CT compared to CI in detecting cartilage invasion and local infiltration in advanced GSCC. Interestingly, while CECT showed FN results

**Table 1**: Primary tumor staging (T) according to the AJCC and summary’s results of different imaging modalities (PET/CT vs. CECT vs. MRI).

| GSCC (n 27); T3 and T4a | PET/CT (n 27) | CECT (n 27) | MRI (n 10) |
|------------------------|---------------|-------------|-----------|
| T4a (n 20)             | 19 TP         | 14 TP       | 7 TP      |
|                        | 1 FN          | 6 FN        | 6 FN      |
| T3 (n 7)               | 6 TN          | 6 TN        | 3 TN      |
|                        | 1 FP          | 1 FP        |           |

TP = true positive; TN = true negative; FP = false positive; FN = false negative.

**Figure 2**: Pt T3 (no cartilage infiltration): PET/CT positive (FP, red arrow) vs. CECT positive (FP, yellow arrow). SUVmax, 19.99; MTV, 8.81 cm³.
Figure 3: ROC Curve for evaluation of sensitivity and specificity of PET/CT. Infiltration PET: AUC 0.902.

Figure 4: ROC Curve for evaluation of sensitivity and specificity of CECT. Infiltration CECT: AUC 0.771.

Table 2: ROC curve for EFS.

| Parameters | AUC (95% CI)     | \(p\) | Cutoff | Sensitivity (95% CI) (%) | Specificity (95% CI) (%) |
|------------|------------------|------|--------|--------------------------|--------------------------|
| MTV        | 0.815 (0.615–0.939) | 0.0002 | 18.6   | 83.3 (51.6–97.9)         | 71.4 (41.9–91.6)         |
| SUV\text{max} | 0.764 (0.562–0.905) | 0.0057 | 6.8    | 100 (75.3–100)           | 42.8 (17.7–71.1)         |
| TLG        | 0.799 (0.602–0.928) | 0.0005 | 78.8   | 84.6 (54.6–98.1)         | 71.4 (41.9–91.6)         |

Table 3: ROC curve for OS.

| Parameters | AUC (95% CI)     | \(p\) | Cutoff | Sensitivity (95% CI) (%) | Specificity (95% CI) (%) |
|------------|------------------|------|--------|--------------------------|--------------------------|
| MTV        | 0.750 (0.543–0.897) | 0.0353 | 22.4   | 83.3 (35.9–99.6)         | 65 (40.8–84.6)           |
| SUV\text{max} | 0.786 (0.586–0.919) | 0.0018 | 17.3   | 71.4 (29.0–96.3)         | 80 (56.3–94.3)           |
| TLG        | 0.775 (0.574–0.912) | 0.0161 | 124    | 85.7 (42.1–99.6)         | 65 (40.8–84.6)           |
in 6/13 patients, only one FN result occurred with PET/CT series (Figure 9), probably related to a very small metabolic volume of primary tumor.

No significant differences were found between PET/CT and MRI. Unfortunately, the latter was performed only in 10 patients not including FN and FP cases highlighted in PET/CT (Figure 10). This precludes any conclusion even if current literature data demonstrated similar results of PET/CT and MRI in local staging of head and neck cancers, although different indications are linked to specific anatomical sites [39–44].

Recent studies have also evaluated the role and the diagnostic value of PET/contrast-enhanced CT (PET/CECT) as one step examination with encouraging data, especially during the initial staging, recognizing it as a valid alternative to the usual combination of two separate imaging procedures. The major advantage, over other imaging methods, is the capability to detect small lymph nodes in the neck zone and to provide more accurate anatomical details of primitive lesion. Even in posttreatment phase, especially after surgery, it appears to be the most suitable restaging tool showing a higher accuracy for diagnosing overall recurrence [45–48].

Considering the high-quality anatomic imaging and resolution of neck MRI and the high sensitivity of metabolic imaging with 18FDG, Kuhn et al. indicated that PET/MRI examination might serve as alternative to PET/CT in the clinical workup of patients with head and neck tumors [49]. Platzek et al. demonstrated the feasibility of whole-body PET/MRI, suggesting a potential improvement in cases with soft tissues infiltration [50]. However, a similar diagnostic accuracy of PET/CT and PET/MRI was reported by Kubiessa (i.e., sensitivity, specificity, PPV, and NPV of 82.7, 81.3, 92.4, and 73.2% for PET/CT vs. 80.5, 88.2, 75.6, and 92.5% for PET/MRI) [51]. The potential advantages offered by this new

**Table 4: Diagnostic accuracy of PET/CT-derived parameters’ cutoff values.**

| Parameters | MTV 18.6 (EFS) (%) | SUVmax 6.8 (EFS) (%) | TLG 78.8 (EFS) (%) | MTV 22.4 (OS) (%) | SUVmax 17.3 (OS) (%) | TLG 124 (OS) (%) |
|-----------|-------------------|---------------------|--------------------|-------------------|---------------------|-----------------|
| Se.       | 85                | 100                 | 85                 | 86                | 71                  | 86              |
| Sp.       | 71                | 43                  | 71                 | 60                | 75                  | 65              |
| PPV       | 73                | 62                  | 73                 | 43                | 50                  | 46              |
| NPV       | 83                | 100                 | 83                 | 92                | 88                  | 93              |
| Acc.      | 78                | 70                  | 78                 | 67                | 74                  | 70              |

**Table 5: Logistic regression for MTV, SUVmax, and TLG.**

| Parameters | (95% CI) | OR | p (3-year EFS) | (95% CI) | OR | p (3-year OS) |
|-----------|---------|----|----------------|---------|----|---------------|
| MTV       | 1.0108 to 1.1803 | 1.0923 | 0.022        | 1.0057 to 1.1271 | 1.0647 | 0.0081        |
| SUVmax    | 1.0098 to 1.3185 | 1.1539 | 0.0165       | 0.9619 to 1.2098 | 1.0788 | 0.1814        |
| TLG       | 1.0015 to 1.0205 | 1.0109 | 0.0022       | 0.9903 to 1.0010 | 1.0588 | 0.0942        |

![Figure 5: ROC curve MTV-EFS.](image)

![Figure 6: ROC curve MTV-OS.](image)
method rely on the better soft tissue contrast on MRI and reduced exposure to radiation compared to PET/CT especially when a CECT is performed.

Anyway, large prospective studies are required to define clinical advantages of PET/MRI, and this new method cannot yet replace PET/CT.
In addition, various quantitative PET/CT-derived parameters have been tested in the pre- and postradiotherapy settings as potential prognostic factors in HNSCC. While SUV was largely studied as PET/CT-derived quantitative parameter, MTV and TLG recently emerged as reliable prognostic marker in solid tumors. In the literature, several studies highlight the possible impact of these prognostic parameter in oropharyngeal and esophageal carcinoma while, so far, there are few published data addressing advanced GSCC [52–56].

MTV and TLG, combining tumor volume and metabolic activity of the entire tumor, are expected to provide a realistic volumetric evaluation of tumor burden with a primary prognostic role in malignant disease [57, 58]. MTV and TLG were introduced in HNC as tools to improve the prognostic stratification and to support other PET/CT-guided radiotherapy plan [18, 19, 23]. These quantitative parameters were analyzed in several series of oropharynx squamous cell carcinoma, and, recently, Wang et al. in a meta-analysis confirmed their superiority compared to SUVmax, highlighting MTV and TLG as prognostic biomarkers to predict outcome in patients with head and neck cancer [59]. Kendi et al. evaluated PET/CT parameters impact to differentiate invasion and penetration of thyroid cartilage highlighting that TLG and MTV had enough power to predict thyroid cartilage invasion and penetration in irradiated patients. In our study, we evaluated, instead, only nonirradiated patients, and above all, in T4a patients, we found extralaryngeal tissues invasion through the thyroid cartilage with infiltration of inner and outer cortices [60].

Considering the data already known in the literature, we analyzed the prognostic value of these parameters in a uniform series of advanced GSCC.

Figure 9: Pt T4 (cartilage infiltration): PET/CT negative (FN, red arrow) vs. CECT negative (FN, yellow arrow). SUVmax, 9.46; MTV, 2.35 cm³.
Our results support baseline MTV as the strongest predictor of outcome for patients with advanced GSCC using two different cutoffs to predict EFS (MTV > 18.6 cm³) and OS (MTV > 22.4 cm³), as described in previous studies focusing on heterogeneous patient series [20, 55].

These data could be extremely useful in patient’s stratification, classifying different relapse risks. PET/CT, in addition to the already approved major clinical tool for monitoring treatment in HNSCC, is therefore a diagnostic procedure capable to select patients undergoing staging, directing them to more or less intensive treatments.

5. Conclusion

Our data suggest a reliable sensitivity and accuracy of PET/CT in the evaluation of local extension (i.e., cartilage invasion and extralaryngeal tissue infiltration) in advanced GSCC in comparison with CECT. PET/CT is a valuable method for initial local staging in addition to its well-established role for neck nodes and distant metastasis assessment. The present study may provide the basis, in our opinion, for prospective studies on larger series of patients; for these particular tumors, it would also be desirable to compare PET/CT and PET/MRI data.

Furthermore, pretreatment MTV provides better prognostic information than other PET/CT-derived parameters; it can be used as an independent long-term predictive factor in patients with advanced GSCC.

Data Availability

The dataset generated during the current study and the data used to support the results are available from the corresponding author on reasonable request.
Disclosure
The abstract was presented in the "12th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN)" and subsequently developed and modified in methods and result section.

Conflicts of Interest
The authors declare no conflicts of interest.

References
[1] D. G. Pfister, S. A. Laurie, G. S. Weinstein et al., “American society of clinical oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer,” Journal of Clinical Oncology, vol. 24, no. 22, pp. 3693–3704, 2006.
[2] L. Barnes, J. W. Eveson, P. Riechart, and D. Sidransky, "8eds pathology and genetics of head and neck tumours," in World Health Organization Classification of Tumours, IARC, Lyon, France, 2005.
[3] H. T. Hoffman, K. Porter, L. H. Karnell et al., "Laryngeal carcinomas," vol. 116, no. 111, pp. 1–13, 2006.
[4] S. B. D. Edge and C. C. Compton, AJCC Cancer Staging Handbook, Springer, New York, NY, USA, 7th edition, 2010.
[5] F. P. Worden, J. Moyer, J. S. Lee et al., "Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion," The Laryngoscope, vol. 119, no. 8, pp. 1510–1517, 2009.
[6] J. A. Casteljins, M. Becker, and R. Hermans, "Impact of cartilage invasion on treatment and prognosis of laryngeal cancer," European Radiology, vol. 6, no. 2, pp. 156–169, 1996.
[7] R. Hermans, "Staging of laryngeal and hypopharyngeal cancer: value of imaging studies," European Radiology, vol. 16, no. 11, pp. 2386–2400, 2006.
[8] W. M. Mendenhall, J. W. Werning, R. W. Hinerman, J. R. Amdurd, and D. B. Villaret, "Management of T1-T2 glottic carcinomas," Cancer, vol. 100, no. 9, pp. 1786–1792, 2004.
[9] R. Murakami, R. Nishimura, Y. Baba et al., "Prognostic factors of glottic carcinomas treated with radiation therapy: value of the adjacent sign on radiological examinations in the sixth edition of the UICC TNM staging system," International Journal of Radiation Oncology*Biology*Physics, vol. 61, no. 2, pp. 471–475, 2005.
[10] Z. Rumboldt, L. Gordon, R. Bonsall, and S. Ackermann, "Imaging in head and neck cancer," Current Treatment Options in Oncology, vol. 7, no. 1, pp. 23–34, 2006.
[11] D. M. Hartl, "Evidence-based practice: management of glottic cancer," Otolaryngologic Clinics of North America, vol. 45, no. 5, pp. 1143–1161, 2012.
[12] J. W. Bailey, E. Abemayor, B. A. Labour, R. A. Hawkins, C. Ho, and H. W. Ward, "Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy," The Laryngoscope, vol. 102, no. 3, pp. 281–288, 1992.
[13] J. W. Braams, J. Pruim, N. J. Freling et al., "Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI," Journal of Nuclear Medicine, vol. 36, no. 2, pp. 211–216, 1995.
[14] H. Schöder, H. W. D. Yeung, M. Gonen, D. Kraus, and S. M. Larson, "Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion," Radiology, vol. 231, no. 1, pp. 65–72, 2004.
[15] V. Kapoor, M. B. Fukui, and B. M. McCook, "Role of 18FFDG PET/CT in the treatment of head and neck cancers: post-therapy evaluation and pitfalls," American Journal of Roentgenology, vol. 184, no. 2, pp. 589–597, 2005.
[16] P. Veit-Haibach, C. Luczak, I. Wanke et al., "TNM staging with FDG-PET/CT in patients with primary head and neck cancer," European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 12, pp. 1953–1962, 2007.
[17] A. T. Kendi, A. Corey, K. R. Magliocca et al., "18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?," European Journal of Radiology, vol. 84, no. 6, pp. 1171–1176, 2015.
[18] D. L. Schwartz, J. Harris, M. Yao et al., "Metabolic tumor volume as a prognostic imaging-based biomarker for head- and-neck cancer: pilot results from radiation therapy oncology group protocol 0522," International Journal of Radiation Oncology*Biology*Physics, vol. 91, no. 4, pp. 721–729, 2015.
[19] V. Paidpally, A. Chirindel, C. H. Chung et al., "FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma," American Journal of Roentgenology, vol. 203, no. 2, pp. W139–W145, 2014.
[20] R. Abgral, N. Keromnes, P. Robin et al., "Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma," European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 4, pp. 659–667, 2014.
[21] S. K. Haerle, K. Strobel, T. F. Hany, D. Sidler, and S. J. Stoeckli, "18F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma," Head & Neck, vol. 32, pp. 319–325, 2009.
[22] F. Arias, V. Chicata, M. J. Garcia-Velloso et al., "Impact of initial FDG PET/CT in the management plan of patients with locally advanced head and neck cancer," Clinical and Translational Oncology, vol. 17, no. 2, pp. 139–144, 2015.
[23] P. H. Ahn and M. K. Garg, "Positron emission tomography/computed tomography for target delineation in head and neck cancers," Seminars in Nuclear Medicine, vol. 38, no. 2, pp. 141–148, 2008.
[24] M. Leclerc, F. Lartigau, T. Lacornerie, J.-F. Daisne, A. Kramar, and V. Grégoire, "Primary tumor delineation based on 18FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy," Radiotherapy and Oncology, vol. 116, no. 1, pp. 87–93, 2015.
[25] L. Ceriani, S. Suriano, T. Ruberto, E. Zucca, and L. Giovanella, "18F-FDG uptake changes in liver and mediastinum during chemotherapy in patients with diffuse large B-cell lymphoma," Clinical Nuclear Medicine, vol. 37, no. 10, pp. 949–952, 2012.
[26] H. Kuno, H. Onaya, S. Fujii, H. Ojiri, K. Otani, and M. Satake, "Primary staging of laryngeal and hypopharyngeal cancer: CT, MR imaging and dual-energy CT," European Journal of Radiology, vol. 83, no. 1, pp. e23–e35, 2014.
[27] P. Zbären, M. Becker, and H. Läng, "Pretherapeutic staging of laryngeal carcinoma: clinical findings, computed tomography, and magnetic resonance imaging compared with histopathology," Cancer, vol. 77, no. 7, pp. 1263–1273, 1996.
laryngeal cartilage: reassessment of criteria for diagnosis at MR imaging," *Radiology*, vol. 249, no. 2, pp. 551–559, 2008.

[29] B. R. Knab, J. K. Salama, A. Solanki et al., "Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma," *Annals of Oncology*, vol. 19, no. 9, pp. 1650–1654, 2008.

[30] D. M. Hartl, "Evidence-based practice," *Otolaryngologic Clinics of North America*, vol. 45, no. 5, pp. 1143–1161, 2012.

[31] M. Becker, "Neoplastic invasion of laryngeal cartilage: radiologic diagnosis and therapeutic implications," *European Journal of Radiology*, vol. 33, no. 3, pp. 216–229, 2000.

[32] B. Y. Huang, M. Solle, and M. C. Weissler, "Larynx," *Otolaryngologic Clinics of North America*, vol. 45, no. 6, pp. 1325–1361, 2012.

[33] W. F. McGuirt, K. M. Greven, J. W. Keyes Jr et al., "Positron emission tomography in the evaluation of laryngeal carcinoma," *Annals of Otology, Rhinology, and Laryngology*, vol. 104, no. 4, pp. 274–278, 1995.

[34] Y. Menda and M. M. Graham, "Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers," *Seminars in Nuclear Medicine*, vol. 35, no. 4, pp. 214–219, 2005.

[35] D. L. Schwartz, E. Ford, J. Rajendran et al., "FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma," *International Journal of Radiation Oncology*•*Biology*•*Physics*, vol. 61, no. 1, pp. 129–136, 2005.

[36] E. Brun, E. Kjellén, J. Tennvall et al., "FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma," *Head & Neck*, vol. 24, no. 2, pp. 127–135, 2002.

[37] B. F. Branstetter IV, T. M. Blodgett, L. A. Zimmer et al., "Head and neck malignancy: is PET/CT more accurate than PET or CT alone?*, *Radiology*, vol. 235, no. 2, pp. 580–586, 2005.

[38] S. Koyasu, Y. Nakamoto, M. Kikuchi et al., "Prognostic value of pretreatment 18F-FDG PET/CT parameters including visual evaluation in patients with head and neck squamous cell carcinoma," *American Journal of Roentgenology*, vol. 202, no. 4, pp. 851–858, 2014.

[39] E. de Monés, C. Bertolus, P. Y. Salaun et al., "Initial staging of squamous cell carcinoma of the oral cavity, larynx and pharynx (excluding nasopharynx). Part 2: remote extension assessment and exploration for secondary synchronous locations outside of the upper aerodigestive tract. 2012 SFORL guidelines," *European Annals of Otorhinolaryngology, Head and Neck Diseases*, vol. 130, no. 2, pp. 107–112, 2013.

[40] M. Comoretto, L. Balestreri, E. Borsatti, M. Cimitan, G. Franchin, and M. Lise, "Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemoradiotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT," *Radiology*, vol. 249, no. 1, pp. 203–211, 2008.

[41] L. Evangelista, A. R. Cervino, S. Chondrogiannis et al., "Comparison between anatomical cross-sectional imaging and 18F-FDG PET/CT in the staging, restaging, treatment response, and long-term surveillance of squamous cell head and neck cancer," *Nuclear Medicine Communications*, vol. 35, no. 2, pp. 123–134, 2014.

[42] J. Müller, M. Hüllner, K. Strobel, G. F. Huber, I. A. Burger, and S. K. Haeber, "The value of 18F-FDG-PET/CT imaging in oral cavity cancer patients following surgical reconstruction," *The Laryngoscope*, vol. 125, no. 8, pp. 1861–1868, 2015.

[43] Y. Suenaga, K. Kitajima, T. Ishihara et al., "FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT," *European Radiology*, vol. 26, no. 4, pp. 1018–1030, 2016.

[44] F. P. Kuhn, M. Hüllner, C. E. Mader et al., "Contrast-enhanced PET/CT imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?*, *Journal of Nuclear Medicine*, vol. 55, no. 4, pp. 551–558, 2014.

[45] I. Platzek, B. Beuthien-Baumann, M. Schneider et al., "PET/MRI in head and neck cancer: initial experience," *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 40, no. 1, pp. 6–11, 2013.

[46] K. Kubiessa, S. Purz, M. Gawlitza et al., "Initial clinical results of simultaneous 18F-FDG PET/MRI in comparison to 18F-FDG PET/CT in patients with head and neck cancer," *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 41, no. 4, pp. 639–648, 2014.

[47] A. Eskander, M. Merdad, J. C. Irish et al., "Volume-outcome associations in head and neck cancer treatment: a systematic review and meta-analysis," *Head & Neck*, vol. 36, no. 12, pp. 1820–1834, 2014.

[48] D. Tamanid, J. Ta, R. Schmid et al., "Prognostic value of volumetric PET parameters in unresectable and metastatic esophageal cancer," *European Journal of Radiology*, vol. 85, no. 3, pp. 540–545, 2016.

[49] S. Chang and S.-J. Kim, "Prediction of recurrence and mortality of locally advanced esophageal cancer patients using pretreatment F-18 FDG PET/CT parameters: intratumoral heterogeneity, SUV, and volumetric parameters," *Cancer Biotherapy and Radiopharmaceuticals*, vol. 31, no. 1, pp. 1–6, 2016.

[50] G. C. Park, J. S. Kim, J. L. Roh, S. H. Choi, S. Y. Nam, and S. Y. Kim, "Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx," *Annals of Oncology*, vol. 24, no. 1, pp. 208–214, 2013.

[51] M. Taghipour, S. Sheikhbahaie, W. Marashdeh, L. Solnes, A. Kiess, and R. M. Subramaniam, "Use of 18F-fluordeoxyglucose-positron emission tomography/computed tomography for patient management and outcome in oropharyngeal...
squamous cell carcinoma,” *JAMA Otolaryngology-Head & Neck Surgery*, vol. 142, no. 1, pp. 79–85, 2016.

[57] R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge, “From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors,” *Journal of Nuclear Medicine*, vol. 50, no. 1, pp. 122S–150S, 2009.

[58] E. H. Dibble, A. C. Lara Alvarez, M.-T. Truong, G. Mercier, E. F. Cook, and R. M. Subramaniam, “18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging,” *Journal of Nuclear Medicine*, vol. 53, no. 5, pp. 709–715, 2012.

[59] L. Wang, J. Bai, and P. Duan, “Prognostic value of 18F-FDG PET/CT functional parameters in patients with head and neck cancer,” *Nuclear Medicine Communications*, vol. 40, no. 4, pp. 361–369, 2019.

[60] A. T. Kendi, A. Corey, K. R. Magliocca et al., “Is there a role for PET/CT parameters to differentiate thyroid cartilage invasion from penetration?,” *European Journal of Radiology*, vol. 85, no. 2, pp. 319–323, 2016.